Adamas Pharmaceuticals Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate ADS-5102, which completed the Phase II/III clinical trial for the treatment of Parkinson's disease, known as levodopa induced dyskinesia.
